Objective: We investigated the relationship between serum levels of endocan and disease activity in patients with Fibromyalgia.
Material method: Forty-five patients who met the 2010 ACR FMS criteria and 28 healthy controls were included in the study. To measure the severity of the disease in patients with fibromyalgia (FMS), the symptom severity scale (SSS), the widespread pain index (WPI), and the Visual Analogue Scale (VAS) were evaluated. Serum endocan, Neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), and CRP values of the patient and control groups were measured.
Results: Patients with FMS had significantly higher serum endocan levels. Mean serum levels of endocan were 0.99 ± 0.28 ng/mL (range: 0.1-2.2) in patients with FMS and 0.63 ± 0.17) ng/mL (range: 0.4 ± 1.1) in control subjects (p <0.05). ROC analysis results for endocan level in the FMS group [AUC (%95 GA): 0.89 (0.81-0.97), sensitivity: %68.9, specificity: %96]. A significant correlation was found between endocan levels and SSS (r:0.33 p: 0.004).
Conclusion: Our study, in which we detected significantly higher endocan levels in patients with FMS compared to controls, supported the use of endocan as an important potential marker for FMS.
Primary Language | English |
---|---|
Subjects | Health Care Administration |
Journal Section | Research Article |
Authors | |
Early Pub Date | August 1, 2023 |
Publication Date | July 19, 2023 |
Submission Date | December 17, 2022 |
Acceptance Date | March 17, 2023 |
Published in Issue | Year 2023 Volume: 40 Issue: 2 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.